Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25076008 | 1.00 | CTSV (0.33) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL27348491 | 0.86 | MAPT (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25879035 | 0.85 | CTSV (0.32) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25076301 | 0.84 | CTSV (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8248147 | 0.82 | MMP2 (0.33) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25650691 | 0.81 | CTSV (0.46) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25757795 | 0.81 | CTSV (0.46) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL29624408 | 0.80 | MMP2 (0.42) | — | |
| SCHEMBL16843376 | 0.79 | NR1H2 (0.35) | CCR2 | |
| SCHEMBL16847037 | 0.79 | NR1H2 (0.35) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | CTSV 2/4885CTSL 4/4885CTSB 17/4885 |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | SERPINB1, PREP, DNPEP | CTSV 5/4885CTSL 4/4885CTSB 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.